32 results
424B5
SLNO
Soleno Therapeutics Inc
29 Sep 23
Prospectus supplement for primary offering
4:51pm
and extensive Phase 3 clinical trials.
For each clinical trial, an independent IRB or independent ethics committee, covering each site proposing to conduct
424B5
SLNO
Soleno Therapeutics Inc
27 Sep 23
Prospectus supplement for primary offering
5:26pm
rigorous and extensive Phase 3 clinical trials.
For each clinical trial, an independent IRB or independent ethics committee, covering each site proposing
8-K
EX-99.1
q5gi1y
19 Dec 22
Soleno Therapeutics Announces Financing Commitment for up to $60 Million
4:49pm
8-K
EX-99.1
t2i9e wrjig5afal8z2p
3 Oct 22
Soleno Therapeutics Announces Initiation of Randomized Withdrawal Study of
9:00am
424B5
0kz5l9x9ageow5h
30 Mar 22
Prospectus supplement for primary offering
5:21pm
424B5
l7m cbdovummc
28 Mar 22
Prospectus supplement for primary offering
4:53pm
424B5
jfl5lgv xfvo7qzge3h
25 Jun 20
Prospectus supplement for primary offering
4:01pm
424B5
p8pycj5v620nutb6ec
23 Jun 20
Prospectus supplement for primary offering
4:06pm